18 The Impact on Management and Outcomes of Benign and High-Risk Breast Lesions After the Introduction of Vacuum-Assisted Excision

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 32

Elles van de Voort, MSc1

1Franciscus Gasthuis & Vlietland Hospital, Rotterdam, the Netherlands.

Background

The aim of this study is to describe the impact of introducing vacuum-assisted excision (VAE) as a treatment for benign and high-risk lesions on the management and outcomes of these lesions.

Methods

This was a single-center, retrospective cohort study with 2 groups. Included were all women ( 16 years) treated for a benign or high-risk lesion. VAE was introduced as a treatment for these lesions in July 2017. The “before” group (BG) included all surgically excised (SE) lesions from January 2016 through June 2017. The “after” group (AG) included all lesions excised utilizing SE or VAE from July 2017 through December 2019. VAE was contraindicated when the tumor was located in proximity to the skin or nipple. Relative contraindications were poor visibility on ultrasound, tumor size > 5 cm, and mobility of the lesion. To evaluate the impact of the introduction of VAE, the proportion of excised lesions and the rates of incomplete excision, recurrence, re-excision, and complications were compared between the 2 groups.

Results

Included were 330 excised lesions in 282 patients. The proportion of excised lesions of all biopsies was higher in the AG (227/1258; 18%) than the BG (103/765; 13%) (P = .007). However, the absolute number of surgical excisions in the operating room decreased after introduction of VAE (65 vs 45 per year, for the BG and AG, respectively). Incomplete excision occurred significantly more in the BG (n = 18; 19%), compared with the AG (n = 15; 7.1%; P = .002), but the number of recurrent lesions was comparable in both groups (BG, 2.9% at a median follow-up of 46 months, vs AG, 0.9% at a median follow-up of 23 months; P = .162). Nine re-excisions were performed, which were evenly distributed over the BG and AG (3.9% vs 2.2%, respectively; P = .385). The proportion of complications was comparable in the BG and AG (4/89 [4.5%] vs 13/205 [6.3%], respectively; P = .805). Complications after SE occurred less frequently but were more severe compared with complications after VAE.

Discussion

The introduction of VAE led to an absolute decrease of benign excisions in the operating room, leaving more time for patients with malignant disease. Although no margin assessment was possible at histologic evaluation after VAE, this did not lead to an increased recurrence rate. With the current shift toward treatment of a less-invasive nature, and ongoing studies on reducing overtreatment of lesions with a low risk of developing into carcinoma, we expect that even more lesions can be excised with VAE in the future.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content